RGS17

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Regulator of G-protein signaling 17
Protein RGS17 PDB 1zv4.png
PDB rendering based on 1zv4.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols RGS17 ; RGS-17; RGSZ2; hRGS17
External IDs OMIM607191 MGI1927469 HomoloGene8242 GeneCards: RGS17 Gene
RNA expression pattern
PBB GE RGS17 220334 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 26575 56533
Ensembl ENSG00000091844 ENSMUSG00000019775
UniProt Q9UGC6 Q9QZB0
RefSeq (mRNA) NM_012419 NM_001161822
RefSeq (protein) NP_036551 NP_001155294
Location (UCSC) Chr 6:
153.33 – 153.45 Mb
Chr 10:
5.83 – 5.92 Mb
PubMed search [1] [2]

Regulator of G-protein signaling 17 is a protein that in humans is encoded by the RGS17 gene.[1][2]

This gene encodes a member of the regulator of G-protein signaling family. This protein contains a conserved, 120 amino acid motif called the RGS domain and a cysteine-rich region. The protein attenuates the signaling activity of G-proteins by binding to activated, GTP-bound G alpha subunits and acting as a GTPase activating protein (GAP), increasing the rate of conversion of the GTP to GDP. This hydrolysis allows the G alpha subunits to bind G beta/gamma subunit heterodimers, forming inactive G-protein heterotrimers, thereby terminating the signal.[2] Along with RGS4, RGS9 and RGS14,[3][4] RGS17 plays an important role in termination of signalling by mu opioid receptors and development of tolerance to opioid analgesic drugs.[5][6]

RGS17 is a putative lung cancer susceptibility gene in the lung cancer associated locus on chromosome 6q in humans.[7] RGS17 is overexpressed in lung and prostate cancers, induces cAMP production, CREB phosphorylation and CREB responsive gene expression[2]. Expression of RGS17 is required for maintenance of proliferation in lung tumor cell lines.[8]

References[edit]

  1. ^ Jordan JD, Carey KD, Stork PJ, Iyengar R (Aug 1999). "Modulation of rap activity by direct interaction of Galpha(o) with Rap1 GTPase-activating protein". J Biol Chem 274 (31): 21507–21510. doi:10.1074/jbc.274.31.21507. PMID 10419452. 
  2. ^ a b "Entrez Gene: RGS17 regulator of G-protein signalling 17". 
  3. ^ Garzón J, Rodríguez-Muñoz M, de la Torre-Madrid E, Sánchez-Blázquez P (June 2005). "Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS". Psychopharmacology 180 (1): 1–11. doi:10.1007/s00213-005-2248-9. PMID 15830230. 
  4. ^ Rodríguez-Muñoz M, de la Torre-Madrid E, Gaitán G, Sánchez-Blázquez P, Garzón J (December 2007). "RGS14 prevents morphine from internalizing Mu-opioid receptors in periaqueductal gray neurons". Cellular Signalling 19 (12): 2558–2571. doi:10.1016/j.cellsig.2007.08.003. PMID 17825524. 
  5. ^ Garzón J, Rodríguez-Muñoz M, López-Fando A, Sánchez-Blázquez P (September 2005). "The RGSZ2 protein exists in a complex with mu-opioid receptors and regulates the desensitizing capacity of Gz proteins". Neuropsychopharmacology 30 (9): 1632–1648. doi:10.1038/sj.npp.1300726. PMID 15827571. 
  6. ^ Rodríguez-Muñoz M, de la Torre-Madrid E, Sánchez-Blázquez P, Garzón J (2007). "Morphine induces endocytosis of neuronal mu-opioid receptors through the sustained transfer of Galpha subunits to RGSZ2 proteins". Molecular Pain 3: 19. doi:10.1186/1744-8069-3-19. PMC 1947952. PMID 17634133. 
  7. ^ You M, Wang D, Liu P, Vikis H, James M, Lu Y, Wang Y, Wang M, Chen Q, Jia D, Liu Y, Wen W, Yang P, Sun Z, Pinney SM, Zheng W, Shu XO, Long J, Gao YT, Xiang YB, Chow WH, Rothman N, Petersen GM, de Andrade M, Wu Y, Cunningham JM, Wiest JS, Fain PR, Schwartz AG, Girard L, Gazdar A, Gaba C, Rothschild H, Mandal D, Coons T, Lee J, Kupert E, Seminara D, Minna J, Bailey-Wilson JE, Amos CI, Anderson MW.Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res. 2009 Apr 15;15(8):2666-74. Epub 2009 Apr 7.
  8. ^ James MA, Lu Y, Liu Y, Vikis HG, You M.RGS17, an overexpressed gene in human lung and prostate cancer, induces tumor cell proliferation through the cyclic AMP-PKA-CREB pathway. Cancer Res. 2009 Mar 1;69(5):2108-16. Epub 2009 Feb 24.

Further reading[edit]